CA2756570C - Peptide ligands for clusterin and uses thereof - Google Patents

Peptide ligands for clusterin and uses thereof Download PDF

Info

Publication number
CA2756570C
CA2756570C CA2756570A CA2756570A CA2756570C CA 2756570 C CA2756570 C CA 2756570C CA 2756570 A CA2756570 A CA 2756570A CA 2756570 A CA2756570 A CA 2756570A CA 2756570 C CA2756570 C CA 2756570C
Authority
CA
Canada
Prior art keywords
peptide
seq
amino acid
acid sequence
clusterin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2756570A
Other languages
English (en)
French (fr)
Other versions
CA2756570A1 (en
Inventor
Feng Ni
Maureen D. O'connor-Mccourt
Dmitri Tolkatchev
Rana Filfil
Anne E.G. Lenferink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Research Council of Canada
Original Assignee
National Research Council of Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Research Council of Canada filed Critical National Research Council of Canada
Publication of CA2756570A1 publication Critical patent/CA2756570A1/en
Application granted granted Critical
Publication of CA2756570C publication Critical patent/CA2756570C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
CA2756570A 2009-04-17 2010-04-15 Peptide ligands for clusterin and uses thereof Active CA2756570C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20291009P 2009-04-17 2009-04-17
US61/202,910 2009-04-17
PCT/CA2010/000566 WO2010118521A1 (en) 2009-04-17 2010-04-15 Peptide ligands for clusterin and uses thereof

Publications (2)

Publication Number Publication Date
CA2756570A1 CA2756570A1 (en) 2010-10-21
CA2756570C true CA2756570C (en) 2019-04-30

Family

ID=42982086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2756570A Active CA2756570C (en) 2009-04-17 2010-04-15 Peptide ligands for clusterin and uses thereof

Country Status (6)

Country Link
US (1) US8629240B2 (https=)
EP (1) EP2419440B1 (https=)
JP (1) JP5861242B2 (https=)
AU (1) AU2010237569B2 (https=)
CA (1) CA2756570C (https=)
WO (1) WO2010118521A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102666585B (zh) 2009-11-24 2015-02-18 阿莱斯亚生物疗法股份有限公司 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途
WO2013123588A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
EP3554638B1 (en) * 2016-12-19 2022-02-02 Morehouse School of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
US11180534B1 (en) 2021-06-04 2021-11-23 Morehouse School Of Medicine Compositions and methods for treating SARS-CoV-2 infections
CN119874833A (zh) * 2025-01-14 2025-04-25 广州中医药大学(广州中医药研究院) Clusterin亲和肽及其修饰的长循环纳米粒的制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012558A1 (en) * 1997-09-10 1999-03-18 Allegheny University Of The Health Sciences Inhibitors of collagen assembly
NZ508812A (en) * 1998-06-12 2002-11-26 Aventis Pasteur Peptides for the prevention or treatment of HIV
CA2328457A1 (en) * 1998-06-20 1999-12-29 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US20050208558A1 (en) 1999-10-19 2005-09-22 Applera Corporation Detection kits, such as nucleic acid arrays, for detecting the expression or 10,000 or more Drosophila genes and uses thereof
ITRM20040098A1 (it) 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
AU2006291990B2 (en) * 2005-09-13 2012-05-31 National Research Council Of Canada Methods and compositions for modulating tumor cell activity
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers

Also Published As

Publication number Publication date
JP2012524029A (ja) 2012-10-11
US20120121507A1 (en) 2012-05-17
EP2419440A1 (en) 2012-02-22
EP2419440B1 (en) 2015-11-11
WO2010118521A1 (en) 2010-10-21
CA2756570A1 (en) 2010-10-21
AU2010237569B2 (en) 2015-04-02
US8629240B2 (en) 2014-01-14
AU2010237569A1 (en) 2011-11-10
JP5861242B2 (ja) 2016-02-16
EP2419440A4 (en) 2013-04-03

Similar Documents

Publication Publication Date Title
US10653801B2 (en) Targeting peptides and methods of use
CA2756570C (en) Peptide ligands for clusterin and uses thereof
US9164097B2 (en) Formulations targeting IGFBP7 for diagnosis and therapy of cancer
US11738099B2 (en) Molecular probes and methods of use
US20140271467A1 (en) Probes and methods of imaging non-hodgkins lymphoma
KR20160102971A (ko) 올리고펩티드 및 그 결합체를 생산하는 방법
CN108623661A (zh) 一种靶向胰腺癌肿瘤细胞的双特异性多肽分子探针及应用
CN109942687A (zh) 68Ga标记EACA修饰c-Met分子成像探针及制备与应用
CA3049508A1 (en) Compositions and methods for cancer imaging and radiotherapy
Leitao et al. Conditionally activated affibody-based prodrug targeting EGFR demonstrates improved tumour selectivity
CN110172084A (zh) 68Ga标记NODAGA修饰c-Met分子探针及制备与应用
AU2020208492B2 (en) Peptide PET/SPECT probes specific to oncoproteins in tumor extracellular matrix
CN109316609B (zh) 选择患者的方法
Xu et al. TMVP1446/GS5, a novel peptide with improved metabolic stability relative to TMVP1446, targets VEGFR-3 for primary tumor and lymph node metastases detection in vivo
CN114555623B (zh) 尿激酶纤溶酶原活性剂受体靶向肽
CN121652237A (zh) 一种EpCAM靶向环肽及其核素小分子探针与应用
Feng et al. A novel peptide multimer for enhanced imaging and multivalent detection of hepatocellular carcinoma
CN119143843B (zh) 一种cxcr4靶向多肽及其制备方法和应用
CN120550151A (zh) 一种检测胶原结构变性的放射性核素标记分子探针及其制备方法与应用
KR101679245B1 (ko) 상피성장인자 수용체를 표적으로 하는 암 진단 또는 영상화용 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150211

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250311

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250311

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317